Stakeholders Still Confused About Breakthrough Standards, Difference From Fast Track
Executive Summary
Agency officials responded to almost 50 queries during a webinar on a draft guidance intended to clarify use of the fast track, breakthrough therapy, priority review and accelerated approval regulatory pathways. Most questions related to the breakthrough program.